Comparison of pharmacogenomic information for drug approvals provided by the national regulatory agencies in Korea, Europe, Japan, and the United States
Pharmacogenomics, which is defined as the study of changes in the properties of DNA and RNA associated with drug response, enables the prediction of the efficacy and adverse effects of drugs based on patients' specific genetic mutations. For the safe and effective use of drugs, it is important...
Saved in:
Main Authors: | Mijin Lee (Author), Ji Min Han (Author), Jaeyeon Lee (Author), Ju Young Oh (Author), Jung Sun Kim (Author), Hye Sun Gwak (Author), Kyung Hee Choi (Author) |
---|---|
Format: | Book |
Published: |
Frontiers Media S.A.,
2023-06-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Mesenchymal Stem Cell Therapies Approved by Regulatory Agencies around the World
by: Luis E. Fernández-Garza, et al.
Published: (2023) -
Small molecule protein kinase inhibitors approved by regulatory agencies outside of the United States
by: Robert Roskoski Jr
Published: (2023) -
Availability and Affordability of Drugs With a Conditional Approval by the European Medicines Agency; Comparison of Korea With Other Countries and the Implications
by: Hye-Young Kwon, et al.
Published: (2018) -
Achievements, Problems, and Future Direction of the Quality Control Program for Special Periodic Health Examination Agencies in Republic of Korea
by: Yong Lim Won, et al.
Published: (2019) -
Age‐related off‐label drug prescribing in pediatric patients in South Korea and consistency of labeling compared to the United States, Europe, and Japan
by: Bojung Park, et al.
Published: (2024)